Associate Professor, Department of Pediatrics Emory University School of Medicine Director, Pediatric Neuro-oncology Basic Research Program Children's Healthcare of Atlanta, Egleston
Winship Cancer Institute of Emory University
Dr. Kenney's research focuses on cell cycle control in cerebellar development and medulloblastoma, a pediatric brain tumor that arises in the cerebellum. These tumors are the most common solid malignancy of childhood. Current treatments for medulloblastomas include surgical resection, chemotherapy, and cranio-spinal irradiation. These therapies lead to a 60% "cure" rate, but survivors are left with life long devastating side effects as a result of these treatment, including cognitive declines, seizures, developmental delays, and premature aging. By gaining increased insight into the cellular and molecular mechanisms that drive tumor establishment and growth, it is Dr. Kenney's hope to identify genes and proteins whose activity could in the future be modulated by drugs and novel small molecules, thereby ameliorating the need for irradiation and chemotherapy.
Targeting Medulloblastoma by Regulating RNA Binding Proteins
RNA-binding proteins (RBP) may play critical roles in medulloblastoma development studying their roles will provide additional direct and indirect targets for the treatment of these tumors and beyond. Researchers will utilize cell lines provided by the Children’s Brain Tumor Network in an effort to identify new targets in the pediatric forms of these tumors.
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature